Literature DB >> 6541663

Immunological comparison between human and rat plasminogen activators in blood and the vessel wall.

A Kjaeldgaard, B Larsson, B Astedt.   

Abstract

To evaluate the rat as an experimental model for plasminogen activator research, the ability of antibodies specific for human tissue type plasminogen activator and urokinase to suppress the plasminogen activator activity in whole plasma and in the vessel wall was studied in both rat and man. Plasminogen activator activity in plasma was assayed on fibrin plates containing plasminogen. Plasminogen activator in the vessel wall was shown by the fibrin side technique. Antibodies against human tissue type melanoma cell activator and urokinase were raised in goats and mixed into the fibrin film or the fibrin plates. In both species antibodies to melanoma cell activator were able to suppress the plasminogen activator activity completely in plasma and in the vessel wall. Anti-urokinase, however, had no suppressing effect. In rat plasma the inhibitory effect on the fibrinolytic activity was seen only with high concentrations of antibodies against melanoma cell activator, which suggests that rat plasminogen activator in plasma and vessel walls is similar to, but not identical with, human tissue type plasminogen activator.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6541663      PMCID: PMC498958          DOI: 10.1136/jcp.37.10.1153

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  18 in total

1.  The demonstration of urokinase antigen in whole blood.

Authors:  M Shakespeare; P Wolf
Journal:  Thromb Res       Date:  1979       Impact factor: 3.944

2.  Purification of urokinase by affinity chromatography.

Authors:  L Holmberg; B Bladh; B Astedt
Journal:  Biochim Biophys Acta       Date:  1976-08-12

Review 3.  The "Hageman" connection: interrelationships of blood coagulation, fibrino(geno)lysis, kinin generation, and complement activation.

Authors:  G Murano
Journal:  Am J Hematol       Date:  1978       Impact factor: 10.047

4.  Dose-response curves in the fibrin plate assay. Fibrinolytic acitivity of proteases.

Authors:  F Haverkate; D W Traas
Journal:  Thromb Diath Haemorrh       Date:  1974-12-31

5.  Fibrinolytic activity of human veins in arms and legs.

Authors:  M Pandolfi; B Robertson; S Isacson; I M Nilsson
Journal:  Thromb Diath Haemorrh       Date:  1968-11-15

6.  Relationship between tissue plasminogen activator and the activators in blood and vascular wall.

Authors:  D C Rijken; G Wijngaards; J Welbergen
Journal:  Thromb Res       Date:  1980-06-15       Impact factor: 3.944

7.  Dexamethasone regulation of plasminogen activator in embryonic and tumor-derived human cells.

Authors:  R Roblin; P L Young
Journal:  Cancer Res       Date:  1980-08       Impact factor: 12.701

8.  Purification and characterization of the plasminogen activator secreted by a rat brain tumor cell line in culture.

Authors:  K Bykowska; D C Rijken; D Collen
Journal:  Thromb Haemost       Date:  1981-10       Impact factor: 5.249

9.  Immunological characterization of multiple weight forms of human cell plasminogen activators.

Authors:  D Vetterlein; P L Young; T E Bell; R Roblin
Journal:  J Biol Chem       Date:  1979-02-10       Impact factor: 5.157

10.  Studies on the specific fibrinolytic effect of human extrinsic (tissue-type) plasminogen activator in human blood and in various animal species in vitro.

Authors:  C Korninger; D Collen
Journal:  Thromb Haemost       Date:  1981-08-28       Impact factor: 5.249

View more
  2 in total

1.  Plasminogen activators in experimental colorectal neoplasia: a role in the adenoma-carcinoma sequence?

Authors:  J S Gelister; M R Lewin; H E Driver; F Savage; M Mahmoud; P J Gaffney; P B Boulos
Journal:  Gut       Date:  1987-07       Impact factor: 23.059

2.  The effect of intravenous tissue-type plasminogen activator in a rat model of embolic cerebral ischemia.

Authors:  P L Penar; C A Greer
Journal:  Yale J Biol Med       Date:  1987 May-Jun
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.